SONNET BIOTHERAPEUTICS HOLDINGS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.82 USD | +2.82% |
|
-9.00% | +4.60% |
| Mar. 11 | Traders Anticipate Inflation Report as US Equities Open Lower on Wall Street | MT |
| Mar. 11 | Top Premarket Gainers | MT |
Financials (USD)
| Sales 2024 * | 117K | Sales 2025 * | - | Capitalization | 5.59M |
|---|---|---|---|---|---|
| Net income 2024 * | -7M | Net income 2025 * | -21M | EV / Sales 2024 * | 47.7 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-1.03
x | P/E ratio 2025 * |
-
| Employees | 12 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.78% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | +2.82% | ||
| 1 week | -9.00% | ||
| Current month | -2.15% | ||
| 1 month | -16.51% | ||
| 3 months | +36.84% | ||
| 6 months | -24.79% | ||
| Current year | +4.60% |
1 week
1.65
2.01
1 month
1.652.23
Current year
1.302.34
1 year
1.0826.40
3 years
1.08840.84
5 years
1.084 989.60
10 years
1.084 989.60
| Managers | Title | Age | Since |
|---|---|---|---|
John Cini
FOU | Founder | 72 | 10-12-31 |
Pankaj Mohan
CEO | Chief Executive Officer | 60 | 20-03-31 |
Jay Cross
DFI | Director of Finance/CFO | 53 | 19-04-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Raghu Rao
BRD | Director/Board Member | 62 | 20-03-31 |
Pankaj Mohan
CEO | Chief Executive Officer | 60 | 20-03-31 |
Donald Griffith
BRD | Director/Board Member | 75 | 20-03-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 1.82 | +2.82% | 22,257 |
| 24-04-18 | 1.77 | +4.12% | 17,984 |
| 24-04-17 | 1.7 | +1.80% | 10,066 |
| 24-04-16 | 1.67 | -7.73% | 28,169 |
| 24-04-15 | 1.81 | -9.50% | 46,275 |
Delayed Quote Nasdaq, April 19, 2024 at 04:30 pm EDT
More quotes
Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage, oncology-focused biotechnology company. The Company's technology, namely Fully Human Albumin Binding (FHAB), utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. The Company designed the FHAB construct to improve drug accumulation in cancer tumors, as well as to extend the duration of activity in the body. Its lead asset, SON-1010, is a fully human single-chain version of Interleukin 12 (IL-12), covalently linked to the FHAB construct, for which it is pursuing clinical development in solid tumors. Its lead clinical-stage asset, SON-080, is a fully human version of IL-6 manufactured in Chinese Hamster Ovary (CHO) cells. SON-080, for its target indications of Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Diabetic Peripheral Neuropathy (DPN). Its pipeline also includes SON-1210, SON-1410 and SON-3015.
Sector
Pharmaceuticals
Calendar
2024-05-07
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.82
USD
Average target price
12.5
USD
Spread / Average Target
+586.81%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +4.60% | 5.43M | |
| +24.60% | 672B | |
| +24.08% | 550B | |
| -5.63% | 351B | |
| +15.37% | 317B | |
| +7.38% | 292B | |
| +3.26% | 211B | |
| +0.78% | 203B | |
| -9.69% | 144B | |
| -6.63% | 141B |
- Stock Market
- Equities
- SONN Stock
